Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 38 min ago
PreprintCC BY 4.0PsyArXiv

Psychedelics, spirituality and drug policy: Harm reduction without compulsory medicalisation

Abstract

Psychedelic experiences can be meaningful and beneficial, including outside clinical treatment. They can also leave people distressed or vulnerable. Spiritual interpretations of these experiences therefore raise a practical question for drug policy: how can people be protected while preserving legitimate uses beyond psychiatry? Drawing on selected human studies and ethical and policy scholarship, this Commentary examines naturalistic benefits, mystical experiences, and concerns about spiritual bypassing and spiritual emergency, whose definitions and empirical support remain uneven. We argue that uncertainty about these risks calls for prevention and proportionate safeguards, but does not, by itself, justify restricting access to psychiatric treatment. We propose four priorities across clinical, community, and religious settings: meaningful consent, protection against exploitation, accessible support after use, and follow-up that records difficulties as well as benefits. Particular attention should be paid to interpretive autonomy: people's freedom to understand and reconsider their experiences without pressure to adopt a provider's beliefs. We claim that the notions of cognitive liberty and freedom of religion or belief strengthen the importance of scrutinising unnecessary restrictions, while retaining duties to prevent coercion and harm. We propose that policy assessment should also include harms associated with prohibition. The aim is to protect people during potentially valuable but vulnerable experiences, including those who seek meaning or well-being without a psychiatric diagnosis.

Related

  1. Feasibility and potential benefits of daily online adaptive radiotherapy for head and neck cancer without margin reduction using an RTT-only workflow
    A.M. Lindegaard, K. Håkansson, A. Appelt +7
    Clinical and translational radiation oncologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Legislative differences in compulsory mental health care for children and adolescents across European countries
    Tjaša Vranetič, Konsta Hakala, Jörg M. Fegert +5
    European Child & Adolescent PsychiatryPeer-reviewedCC BY 4.0Full text1 citedPsychiatry & mental healthPMC
  3. Myopia prevalence among students in nine-year and independent compulsory education schools: a retrospective cross-sectional study.
    Hui Zhou, Baogang Xing, Shuang Tian +3
    BMC ophthalmologyPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCPMC
  4. Pharmaceutical access in medical security systems and health policy mobilization: cross-national evidence on TRIPS compulsory licensing from 2001 to 2024
    Dongmei Wang
    Frontiers in public healthPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCCrossref
  5. Caution before canonisation: a clinical and implementation science perspective on psychedelics.
    Andreas Paris, Foteini Thoma, Aikaterini Velentza +2
    Frontiers in psychiatryPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMCCrossref
BibTeX
@misc{fauvel2026psychedelics,
  title = {{Psychedelics, spirituality and drug policy: Harm reduction without compulsory medicalisation}},
  author = {Baptiste Fauvel},
  howpublished = {PsyArXiv},
  year = {2026},
  month = oct,
  doi = {10.31234/osf.io/jxky8_v1},
  url = {https://osf.io/preprints/psyarxiv/jxky8_v1/},
  note = {CC BY 4.0},
}
RIS
TY  - UNPB
TI  - Psychedelics, spirituality and drug policy: Harm reduction without compulsory medicalisation
AU  - Baptiste Fauvel
PY  - 2026
DA  - 2026/10/22
PB  - PsyArXiv
DO  - 10.31234/osf.io/jxky8_v1
UR  - https://osf.io/preprints/psyarxiv/jxky8_v1/
AB  - Psychedelic experiences can be meaningful and beneficial, including outside clinical treatment. They can also leave people distressed or vulnerable. Spiritual interpretations of these experiences therefore raise a practical question for drug policy: how can people be protected while preserving legitimate uses beyond psychiatry? Drawing on selected human studies and ethical and policy scholarship, this Commentary examines naturalistic benefits, mystical experiences, and concerns about spiritual bypassing and spiritual emergency, whose definitions and empirical support remain uneven. We argue that uncertainty about these risks calls for prevention and proportionate safeguards, but does not, by itself, justify restricting access to psychiatric treatment. We propose four priorities across clinical, community, and religious settings: meaningful consent, protection against exploitation, accessible support after use, and follow-up that records difficulties as well as benefits. Particular attention should be paid to interpretive autonomy: people's freedom to understand and reconsider their experiences without pressure to adopt a provider's beliefs. We claim that the notions of cognitive liberty and freedom of religion or belief strengthen the importance of scrutinising unnecessary restrictions, while retaining duties to prevent coercion and harm. We propose that policy assessment should also include harms associated with prohibition. The aim is to protect people during potentially valuable but vulnerable experiences, including those who seek meaning or well-being without a psychiatric diagnosis.
ER  -